|
NRG postpones HFR reactor restart
 December 6, 2012 -- Radiopharmaceutical producer Nuclear Research and Consultancy Group (NRG) on November 30 announced that it has postponed the restart of its High Flux Reactor (HFR) in Petten, the Netherlands, after it discovered an abnormality in the cooling water system of the reactor.
To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below.
(Helptag:PaywallArticleLoginMessage)
| |
|
|
New AuntMinnie.com Members
|
Becoming a Member is FREE!
|
Real-time radiology-specific news
Case of the Day and Teaching Files
Focused topics digital communities
Lively, discussion groups
Medical imaging bookstore
SalaryScan
Job Boards
OnLine CMe/CE
Bookstore, market reports, more …
Conference Calendar
User-controlled eNewsletters
… registration is FREE and easy!
|
| |
|
The problem was found as NRG was preparing to start the reactor, which produces the radioisotope molybdenum-99 (Mo-99), following planned maintenance that began on November 11.
NRG conducted a visual inspection as part of its safety analysis and has reported the status of its investigation to authorities. There is no risk to staff or the environment, NRG said.
NRG gave no indication of when the HFR may resume activity, but stated "all efforts are being made to maintain continuity in the production of medical isotopes in an optimal way. NRG expects to be able to provide more information by mid-December."
In the meantime, Mallinckrodt, the pharmaceutical business unit of Covidien, told its customers in a November 30 letter that it expects to meet demand for medical isotopes "in the coming weeks."
Mallinckrodt noted that it has Mo-99 sources in Belgium, Poland, and South Africa, as well as an agreement with medical isotope provider Nordion in Canada. | |
|